Dermatology Times has published a set of evidence-based safety guidelines covering cosmetic dermatology procedures and treatments during pregnancy and lactation, aiming to give clinicians a practical reference for one of the most underserved areas of aesthetic practice.

The guidance addresses a persistent gap: patients who are pregnant or breastfeeding are routinely excluded from aesthetic treatment because practitioners lack a clear, evidence-backed framework for deciding what is safe, what should be deferred, and what is contraindicated. Rather than a blanket prohibition, the Dermatology Times material works through the categories of concern that clinicians actually encounter in practice.

Why dedicated guidelines were needed

Most aesthetic treatments and cosmetic ingredients have never been tested in controlled studies on pregnant or lactating women, for obvious ethical reasons. That leaves clinicians extrapolating from animal data, pharmacokinetic reasoning, and case reports. The result has been wide variation in practice: some providers refuse all treatments outright, others proceed on informal judgment.

Evidence-based guidance of this kind serves two audiences at once. For dermatologists and aesthetic practitioners, it defines a defensible standard of care. For patients, it distinguishes between treatments that carry a plausible risk and those where the safety profile supports continued use under appropriate conditions.

What the guidelines cover

The Dermatology Times framework walks through the major categories of cosmetic dermatology as they apply to pregnant and lactating patients:

• Topical skincare actives and cosmetic ingredients, evaluated for systemic absorption and exposure during pregnancy and breastfeeding
• Injectable treatments and minimally invasive aesthetic procedures, assessed against available safety evidence
• Energy-based devices and laser procedures, where treatment decisions hinge on local versus systemic effects
• General principles for counseling patients who are pregnant, planning pregnancy, or nursing, including when to postpone treatment until after delivery or weaning

The through-line of the guidance is risk stratification: instead of treating "cosmetic dermatology" as a single category to be approved or rejected wholesale, it separates modalities by mechanism, absorption profile, and the biological context of pregnancy and lactation.

What this means for practice menus and compliance

For clinics, the practical value of a published, evidence-based reference is operational. Treatment consent protocols, pre-treatment screening questionnaires, and staff training all need a documented basis for accepting or declining pregnant and lactating patients. Guidance like this gives clinics something to point to when they draw those lines.

It also matters for formulation-adjacent conversations. Practitioners field daily questions from pregnant patients about which retinoids, hydroxy acids, and other common actives they can keep using. Clinics that can answer those questions from an evidence-based framework, rather than caution by default, hold onto patient relationships through a life stage that can otherwise interrupt a treatment plan for a year or more.

The counseling dimension

A recurring theme in the guidance is that the decision is rarely binary. Many treatments fall into a middle zone where the evidence is limited but reassuring, or where the risk depends on timing — first trimester versus third, pregnancy versus lactation. Structured counseling, with documented patient discussion, becomes as important as the go/no-go decision itself.

That framing shifts the clinician's role from gatekeeper to adviser. Patients who are told simply "come back after the baby" often do not come back. Patients who are given a graded answer — what is safe now, what can wait, and why — tend to stay engaged with the practice through pregnancy and postpartum.

What to watch next

The Dermatology Times guidelines are a clinical reference, not a regulatory document, but they are the type of evidence synthesis that tends to migrate into professional society recommendations over time. Practitioners should watch for whether the major dermatology and aesthetic medicine societies incorporate the same categorization into their own position statements, and whether manufacturers of energy-based devices and injectables begin adding pregnancy and lactation data sections to their clinical dossiers in response to demand for exactly this kind of guidance.